Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc. (NYSE: EBS) regularly issues news and updates that reflect its focus on public health threats and pharmaceutical preparation manufacturing. Company announcements highlight developments across its commercial naloxone franchise, medical countermeasures portfolio, manufacturing network and financial performance, providing context for how Emergent pursues its stated mission to protect and save lives.
News items frequently cover product and regulatory milestones, such as U.S. Food and Drug Administration approvals and supplemental applications. Examples include FDA approval of over‑the‑counter NARCAN® Naloxone HCl Nasal Spray 4 mg and approval of a supplemental Biologics License Application for raxibacumab manufacturing at Emergent’s Winnipeg, Canada facility. Releases also describe new packaging options, such as the NARCAN® Nasal Spray carrying case designed to make naloxone easier to carry and more discreet.
Emergent’s news flow also features government contracts and contract modifications for medical countermeasures. Recent announcements describe delivery orders and options to supply BioThrax® (Anthrax Vaccine Adsorbed), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), TEMBEXA® and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to U.S. government agencies responsible for preparedness and response.
Investors and observers can also find financial and corporate updates, including quarterly earnings releases, segment performance commentary, debt prepayments under term loan facilities, and notices of presentations at healthcare conferences. Additional news addresses board‑level changes and corporate governance matters.
Other communications focus on public health initiatives and collaborations, such as support for opioid poisoning awareness observances, partnerships aimed at increasing workplace access to naloxone, and collaboration with PANTHER and Africa CDC on the MpOx Study in Africa. Together, these updates offer insight into how Emergent’s products, contracts, research collaborations and financial decisions relate to its role in addressing health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Emergent BioSolutions (NYSE: EBS) announced that Joe Papa, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 PM PST. An audio link to the session will be available and kept live for up to 30 days. The company said its presentation slides will be posted on the Investors section of the Emergent website at the time of the presentation.
Emergent BioSolutions (NYSE: EBS) announced that the U.S. FDA approved its supplemental BLA on Dec 12, 2025 to add the company's Winnipeg, Canada facility as a drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for treatment and prophylaxis of inhalational anthrax.
The Winnipeg site is described as USMCA-compliant with over 45 years of therapeutics manufacturing experience and capabilities for drug substance, fill/finish, and analytical testing. The approval follows a May 2024 operational plan to consolidate manufacturing in Winnipeg and Lansing as part of a multi-year transformation strategy.
Emergent BioSolutions (NYSE: EBS) marks the 10-year anniversary of the U.S. FDA approval of NARCAN® Nasal Spray, the first FDA‑approved nasal naloxone spray for emergency opioid overdose treatment, originally approved in November 2015 and later authorized OTC in March 2023.
The company highlights milestones: >85 million doses distributed since 2016, the 2018 acquisition of Adapt Pharma, launch of NARCANDirect, Project NEXUS real‑world evidence efforts, and product extensions including wall unit kits and convenience kits. Emergent cites a nearly 32% decline in opioid overdose deaths reported by CDC in 2024 and reaffirms commitment to naloxone access.
Emergent BioSolutions (NYSE: EBS) announced that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14, 2025 after 19 years of service.
Dr. Sullivan joined the board in 2006 and most recently served as chair of the compensation committee and as a member of the nominating and corporate governance committee. The company noted his experience in healthcare, government and biotechnology and cited his role guiding decisions during Emergent’s multi-year transformation. Dr. Sullivan previously served as president of Morehouse School of Medicine and as Secretary of the Department of Health and Human Services.
Emergent BioSolutions (NYSE: EBS) reported Q3 2025 total revenue $231.1M, beating the high end of guidance by $21.0M. Q3 net income was $51.2M (margin 22%) and adjusted EBITDA was $87.8M (margin 38%).
The company noted adjusted gross margin 61% (up 200 bps YoY), sequential naloxone revenue growth led by NARCAN nasal spray, and raised full-year 2025 revenue and profitability guidance. Emergent reported 11 MCM contract modifications/orders in 2025 and that international customers represent 34% of MCM orders YTD. Year-to-date revenue was $594.2M, down versus prior year.
Emergent BioSolutions (NYSE: EBS) released a survey of ~250 U.S. policy opinion leaders on Oct 28, 2025 showing heightened concern about biological threats and U.S. preparedness.
Key findings: 65% say the likelihood of a biological attack is rising, 45% say the U.S. is unprepared, 73% believe a biological attack would be easier to carry out than a nuclear one, and nearly 90% support continued U.S. leadership and government backing for biotech/biodefense. Emergent highlighted its >25 years of countermeasure experience and North American BSL‑2/3 manufacturing capabilities for anthrax, botulism, smallpox and viral hemorrhagic fevers.
Emergent BioSolutions (NYSE: EBS) will report third quarter 2025 financial results and host a conference call on Wednesday, October 29, 2025 at 5:00 PM ET. The call will be available live via webcast and by telephone with advance registration; registered telephone participants receive a confirmation email with dial-in numbers, a unique passcode, and registrant ID. A replay will be accessible on the company’s Investors page.
Emergent BioSolutions (NYSE:EBS) has reaffirmed its commitment to combating the opioid crisis through awareness, education, and expanded naloxone access during several September observances. The company offers two key products: NARCAN® Nasal Spray 4 mg (first FDA-approved over-the-counter opioid overdose reversal treatment) and KLOXXADO® Nasal Spray 8 mg.
The company is actively engaging with partners like the National Safety Council to increase workplace access to naloxone. Emergent recently received the Green Cross for Safety Advocate Award alongside Amazon for their efforts to expand naloxone availability in workplaces. The company is also supporting various initiatives including SOAR West Virginia Save a Life Day and Truth Pharm's National Trail of Truth event.
Emergent BioSolutions (NYSE:EBS) has secured new purchase orders worth $29 million from an international government partner for medical countermeasures (MCM). The multi-product supply agreement includes countermeasures for smallpox, anthrax, and botulism threats.
The company will receive $26 million in 2025, adding to over $100 million in sales already generated year-to-date for its MCM portfolio outside the U.S. This marks the second procurement by the same government this year, reflecting increased global focus on defense preparedness, particularly among NATO members who are raising defense expenditures from 2% to 5% of GDP.
Emergent BioSolutions (NYSE:EBS) has secured a $17 million contract modification from BARDA to supply TEMBEXA® (brincidofovir) oral suspension, a smallpox antiviral treatment. The modification follows FDA's recent approval of manufacturing scale-up for the oral suspension formulation.
The contract builds upon previously announced options from September 2024 under Emergent's existing 10-year contract with BARDA. The oral suspension formulation is specifically designed for patients who have difficulty swallowing due to age or medical conditions, strengthening the U.S. government's preparedness against potential smallpox outbreaks.